Aditxt, Inc.

Equities

ADTX

US0070256047

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
2.39 ^USD	-5.53%		+1.70%	-63.95%

Apr. 16	Aditxt, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Apr. 02	Appili Therapeutics To be Acquired by Aditxt, Inc.	MT

Aditxt, Inc. Announces Resignation of Matthew Shatzkes as Chief Legal Officer, General Counsel and Corporate Secretary

July 27, 2023 at 05:19 pm EDT

On July 21, 2023, Matthew Shatzkes tendered his resignation as Chief Legal Officer, General Counsel and Corporate Secretary of Aditxt, Inc. In connection with his resignation, the Company entered into a Separation Agreement and General Release. Pursuant to the Separation Agreement, Mr. Shatzkes employment with the Company will terminate on August 4, 2023.

Latest news about Aditxt, Inc.

Aditxt, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 16	CI
Appili Therapeutics To be Acquired by Aditxt, Inc.	Apr. 02	MT
Aditxt, Inc. announced that it has received $6.000003 million in funding	Jan. 03	CI
Wall Street Set to Open 2024 Lower Amid Rise in Oil Prices, Ahead of Manufacturing, Construction Data	Jan. 02	MT
Top Premarket Decliners	Jan. 02	MT
Aditxt, Inc. announced that it expects to receive $6.000003 million in funding	Dec. 28	CI
Sector Update: Health Care Stocks Advance Late Afternoon	Dec. 12	MT
Top Midday Gainers	Dec. 12	MT
Top Premarket Gainers	Nov. 30	MT
Aditxt, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Aditxt, Inc. Announces Board Changes	Nov. 09	CI
Aditxt Closes $10 Million Private Placement	23-09-07	MT
Aditxt, Inc. announced that it has received $10 million in funding	23-09-05	CI
Top Premarket Decliners	23-09-05	MT
Top Premarket Decliners	23-09-01	MT
Aditxt Prices $10 Million Private Placement of Common Shares	23-09-01	MT
Aditxt, Inc. announced that it expects to receive $10 million in funding	23-08-30	CI
Aditxt, Inc. Enters into Business Loan and Security Agreement	23-08-28	CI
Top Premarket Decliners	23-08-21	MT
Aditxt to Implement 1-for-40 Reverse Stock Split	23-08-17	MT
Aditxt, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Aditxt, Inc. Announces Resignation of Matthew Shatzkes as Chief Legal Officer, General Counsel and Corporate Secretary	23-07-27	CI
Aditxt, Inc. announced that it has received $1.75 million in funding	23-07-23	CI
Certain Option of Aditxt, Inc. are subject to a Lock-Up Agreement Ending on 24-JUL-2023.	23-07-23	CI
Certain Warrants of Aditxt, Inc. are subject to a Lock-Up Agreement Ending on 24-JUL-2023.	23-07-23	CI

Chart Aditxt, Inc.

Duration

Period

More charts

Company Profile

Aditxt, Inc. is a biotech company focused on discovering, developing, and deploying health innovations. It develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying, developing, and commercializing new ways to treat infectious diseases, and Pearsanta, Inc., offering personalized lab testing, backed by CLIA-certified and CAP-accredited monitoring center. Adimune, Inc's immune modulation product candidate, ADI-100, is based on the Apoptotic DNA Immunotherapy platform technology, utilizes a novel approach that mimics the way bodies naturally induce tolerance to own tissues. It also offers electroencephalography (EEG) brain monitoring technologies and devices, including NeuroCap and NeuroEEG for telehealth and tele-neurology applications.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ADITXT, INC.	-63.95%	3.98M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs